FDA Grants Napabucasin Orphan Drug Status for Gastric Cancer
Boston Biomedical announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for its investigational compound, napabucasin, for the treatment of gastric cancer, including gastroesophageal junction (GEJ) cancer.